fda warning compounded semaglutide safety 2024 2025 Drug Recalls and Warnings: Recalls for and Tirzepatide, Wegovy; Facility Letters FDA restricts non-approved compounded GLP-1

PubMed, Embase, and the Cochrane Library were searched using keyword combinations related to GLP-1 receptor agonists, dual GLP-1/GIP agonists, and GI adverse events, from the inception of the database up to March 2025

At higher doses: Some participants experienced dysesthesia , an abnormal skin sensation Discontinuation rates were higher than placebo A portion of discontinuations were attributed to excessive weight loss , underscoring the importance of careful dosing and clinical oversight Additional late-stage trials are ongoing and will further clarify safety, tolerability, and optimal dosing strategies

Tirzepatide 2.5mg Tirzepatide 2.5mg starting-dose research vial entry-level dual GIP/GLP-1 receptor agonist for pilot studies and dose-titration protocols

If you experience persistent gastrointestinal discomfort throughout the week, your PlexusDx provider may recommend a slower dose escalation schedule or a microdose protocol, which delivers lower weekly amounts over an extended ramp-up period

Also, compounded drugs may be useful in times of drug shortages